TELO Telomir Pharmaceuticals Corp: Enterprise Value to EBITDA Ratio
Telomir Pharmaceuticals (TELO) is accelerating the development of small molecules to stimulate telomerase in an effort to reverse inflammatory processes. The business leverages the global anti-aging market, focusing on therapies for anemia and pulmonary fibrosis. Price action based on the EV/EBITDA metric, which currently stands at 0.00, underscores the valuation's dependence on the success of clinical trials and the stability of long-term capital within the life-extension sector.
Comprehensive metric breakdowns and analytics for Telomir Pharma (TELO)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Telomir Pharmaceuticals|TELO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Telomir Pharmaceuticals, Inc.|TELO - Company Cumulative Indebtedness|Debts to Book Capitalization Telomir Pharmaceuticals Corp|TELO - Long-Term Debt|Company Short-Term Debt Telomir Pharmaceuticals|Quick Liquidity telomirpharma.com
- financial results and valuation multiples details:
TELO - Company Net Income|Expected Profit Telomir Pharmaceuticals|TELO - Price to Earnings Ratio|Forward P/E Multiple Telomir Pharmaceuticals Inc|TELO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharmaceuticals Inc|TELO - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Telomir Pharmaceuticals|TELO - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months telomirpharma.com|TELO - Earnings per share trend in current year|Earnings growth forecast for next year Telomir Pharmaceuticals
- company sales and revenue statistics:
General company analysis:Telomir Pharmaceuticals Inc TELO
This fundamental indicator compares the total enterprise value to its operating profit before taxes and amortization, allowing for an assessment of business efficiency while accounting for the debt load. By analyzing the EV/EBITDA ratio in conjunction with the capital structure, an investor can discern the real value of assets at Telomir Pharmaceuticals (TELO), where the automation of drug synthesis is expected to offset the high costs of multi-year clinical trials conducted under scientific supervision.
Competitor analysis
Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals Inc - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company PLC) - EV/EBITDA Multiple|Company Value to EBITDA alvotech.com ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia (LQDA)|GLPG (Galapagos) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals Inc)|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals Inc (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Theravance Biopharma Inc (TBPH)|AQST (aquestive.com) - EV/EBITDA Multiple|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding Corp. - Enterprise Value to Operating Income Before Depreciation|China SXT Pharmaceuticals - Enterprise Value to EBITDA Ratio|EPRX: Enterprise Value to Operating Income Before Depreciation|BHST: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Invizyne|Oramed Pharmaceuticals Inc. (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ENTX (Entera Bio Ltd) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio HYFT|ABVC BioPharma, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CPIX|Total Company Value to Operating Income Before Depreciation Ratio Quantum BioPharma Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen FGEN|RANI (Rani Therapeutics Inc) - Company Value to Operating Income Before Depreciation Ratio|SNYR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RLYB (Rallybio)|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix, Inc.|PTHL (Pheton Holdings Ltd) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio
